OBJECTIVE: To investigate the mechanisms of metastasis formation in metastatic human pancreatic cancer, we examined the enhancement in integrin expression, and adherence to and invasiveness into extracellular matrix (ECM) proteins of human pancreatic cancer cells after exposure to interleukin (IL)-1alpha. METHODS: Expression of IL-1 receptor type I (IL-1RI) and alterations in integrin subunits by IL-1alpha were examined by flow-cytometric analysis and by cellular enzyme-linked immunosorbent assay in four human pancreatic cancer cell lines (BxPC-3, PaCa-2, PANC-1, and SW1990), respectively. In addition, assays of cancer cell adhesion and invasion to ECM proteins were performed to investigate whether increased integrin expression affected the adhesive and invasive interaction between cancer cells and the putative integrin ECM ligands. Furthermore, immunohistochemistry was used to assess integrins and IL-1R1 expression in pancreatic tissues. RESULTS: In metastatic cancer cells, expression of the alpha(6) subunit was enhanced by IL-1alpha treatment. While metastatic cancer cells exhibited preferential adherence to and invasion into laminin, these properties were enhanced by IL-1alpha. The alpha(6) subunit and IL-1RI were strongly expressed in pancreatic tissues from pancreatic cancer patients with liver metastasis. CONCLUSIONS: In pancreatic cancer, IL-1alpha enhanced alpha(6)beta(1)-integrin expression, probably via increased IL-1RI levels. Our results indicated that alpha(6)beta(1)-integrin and IL-1RI expression may play important roles in metastasis formation. Copyright 2003 S. Karger AG, Basel
OBJECTIVE: To investigate the mechanisms of metastasis formation in metastatic humanpancreatic cancer, we examined the enhancement in integrin expression, and adherence to and invasiveness into extracellular matrix (ECM) proteins of humanpancreatic cancer cells after exposure to interleukin (IL)-1alpha. METHODS: Expression of IL-1 receptor type I (IL-1RI) and alterations in integrin subunits by IL-1alpha were examined by flow-cytometric analysis and by cellular enzyme-linked immunosorbent assay in four humanpancreatic cancer cell lines (BxPC-3, PaCa-2, PANC-1, and SW1990), respectively. In addition, assays of cancer cell adhesion and invasion to ECM proteins were performed to investigate whether increased integrin expression affected the adhesive and invasive interaction between cancer cells and the putative integrin ECM ligands. Furthermore, immunohistochemistry was used to assess integrins and IL-1R1 expression in pancreatic tissues. RESULTS: In metastatic cancer cells, expression of the alpha(6) subunit was enhanced by IL-1alpha treatment. While metastatic cancer cells exhibited preferential adherence to and invasion into laminin, these properties were enhanced by IL-1alpha. The alpha(6) subunit and IL-1RI were strongly expressed in pancreatic tissues from pancreatic cancerpatients with liver metastasis. CONCLUSIONS: In pancreatic cancer, IL-1alpha enhanced alpha(6)beta(1)-integrin expression, probably via increased IL-1RI levels. Our results indicated that alpha(6)beta(1)-integrin and IL-1RI expression may play important roles in metastasis formation. Copyright 2003 S. Karger AG, Basel
Authors: Kiyoshi Yoshimura; Kristen F Meckel; Lindsay S Laird; Christina Y Chia; Jang-June Park; Kelly L Olino; Ryouichi Tsunedomi; Toshio Harada; Norio Iizuka; Shoichi Hazama; Yukihiko Kato; Jesse W Keller; John M Thompson; Fumin Chang; Lewis H Romer; Ajay Jain; Christine Iacobuzio-Donahue; Masaaki Oka; Drew M Pardoll; Richard D Schulick Journal: Cancer Res Date: 2009-09-08 Impact factor: 12.701
Authors: Hua Zhong; Baohui Han; Irina L Tourkova; Anna Lokshin; Alan Rosenbloom; Michael R Shurin; Galina V Shurin Journal: Clin Cancer Res Date: 2007-09-15 Impact factor: 12.531
Authors: Bailee H Sliker; Benjamin T Goetz; Raina Barnes; Hannah King; H Carlo Maurer; Kenneth P Olive; Joyce C Solheim Journal: Exp Cell Res Date: 2020-03-16 Impact factor: 3.905
Authors: John A Conti; Timothy J Kendall; Adrian Bateman; Thomas A Armstrong; Andrew Papa-Adams; Qian Xu; Graham Packham; John N Primrose; R Christopher Benyon; John P Iredale Journal: Clin Cancer Res Date: 2008-10-15 Impact factor: 12.531